Document is current
Any future updates will be listed below
-
Authors
Zhao, Zhongchao https://orcid.org/0000-0002-3736-6677
Ledezma, Debbie K.
Affonso de Oliveira, Jessica Fernanda
Omole, Anthony O. https://orcid.org/0000-0002-2323-2790
Steinmetz, Nicole F. https://orcid.org/0000-0002-0130-0481
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA253615, K99-CA283299)
Shaughnessy Family Fund for Nano-ImmunoEngineering (nanoIE) at UCSD to N.F.S Cancer Therapeutics Training (CT2) program at the UCSD Moores Cancer Center to D.L.
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 19 May 2025
First Online: 30 May 2025
Competing interests
: N.F.S. is a co-founder and CEO of and has equity in PlantiosX Inc. She is also a co-founder of and has equity in Mosaic ImmunoEngineering Inc. and co-founder and manager of Pokometz Scientific LLC, under which she is a paid consultant to Flagship Labs 95 Inc. The other authors declare no competing interests.
